Gilead­'s new­ly de­part­ed R&D chief re-emerges as CEO of a ri­val hep B biotech look­ing to make a come­back

Just a few weeks af­ter tak­ing his $1.1 mil­lion sev­er­ance check from Gilead, John McHutchi­son has re-emerged as the new CEO of As­sem­bly Bio­sciences $ASMB, which has seen its share price swoon as in­vestors lost con­fi­dence in its abil­i­ty to com­pete with Gilead with its ex­per­i­men­tal he­pati­tis B drug.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER